Live Alembic Pharmaceuticals Share Price Chart
O 961.95
H 961.95
L 961.95
VOL 33
Alembic Pharmaceuticals Performance
Days Range
Alembic Pharmaceuticals Fundamentals
ROCE (TTM) | 11.13 |
P/E Ratio (TTM) | 33.23 |
P/B Ratio | 4.39 |
Industry P/E | 36.19 |
Debt to Equity | 0.19 |
ROE | 11.89 |
EPS (TTM) | 30.03 |
Dividend Yield | 0.8 |
Book Value | 227.41 |
Face Value | 2 |
Alembic Pharmaceuticals Financials
Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | |
---|---|---|---|---|
Net Sales | 1,406.45 | 1,486.15 | 1,594.93 | 1,630.57 |
Expenses | 1,268.35 | 1,353.64 | 1,454.24 | 1,433.65 |
Profit before tax | 116.17 | 129.76 | 134.64 | 184.59 |
Operating Profit | 152.6 | 120.6 | 136.56 | 180.45 |
Net Profit | 152.6 | 120.6 | 136.56 | 180.45 |
EPS in Rs | 7.76 | 6.14 | 6.95 | 9.23 |
About Alembic Pharmaceuticals
History of Alembic Pharmaceuticals Limited
Incorporated in 2010, Alembic Pharmaceuticals Limited is involved in the manufacturing and trading Active Pharmaceutical Intermediates (API) and finished dosage formulations.
The company started in 1904, with the manufacture of alcohol and tinctures in Vadodara. Later, in 1940, they started the production of vitamins, cough syrups, sulphur drugs and tonics. In 1961, the company inaugurated the Penicillin plant. In 1967, the company started bulk manufacturing of Vitamin B12, and later, in 1971, they manufactured Erythromycin, the first in India. This was followed by the launch of Althrocin. By 1997, Althrocin had become a top-selling brand in India.
In 2001, the company started the production of Cephalosporin C. In 2011, the company was demerged from the Alembic Group and Alembic Pharmaceuticals Limited was listed as a separate company. In 2012, Alembic Pharmaceuticals Limited entered the dermatology division with 8 products. The next year, the company had its first Non-Disclosure Agreement (NDA) with a partner and started filing in Brazil, EU and Australia. In 2015, the company launched Aripiprazole, established front-end operations in the United States, and shifted to in-house marketing,
In 2016, they had a JV with Orbicular – Aleor Dermaceutical Limited and started developing dermatology products for overseas markets. In 2017, they opened another manufacturing facility for oncology medicines. In 2018, Alembic Pharmaceuticals Limited’s Aleor’s dermatology facility got approval from the Food and Drug Administration (FDA). The next year i.e., in 2019, the company made another JV to enter the Chinese market. In 2020, the company’s products in the US market made $250 million in sales.
As of March 2023, Alembic Pharmaceuticals Limited has 9 manufacturing plants and 2 R&D centres in India. They serve 33 states (including Union Territories) in India and 77 countries worldwide.
Business Segments of Alembic Pharmaceuticals Limited
There are 3 primary business segments of the company, which are as follows:
- India Formulations: Under this segment, the company develops and delivers speciality medicines that cater to various chronic and acute therapies. The therapies include dermatology, ophthalmology, dermatology, orthopaedic, cardiology, anti diabetic, anti infection, gynaecology, animal health, and more. They have an extensive product range featuring 185 brands.
- International Generics: Under this segment, the company manufactures products and caters to its global partners.
- Active Pharmaceutical Ingredients: Alembic Pharmaceuticals manufactures APIs for select formulation products under this segment.
As of March 31, 2023, the subsidiaries of Alembic Pharmaceuticals Limited are as follows:
- Okner Realty LLC: This wholly-owned subsidiary of thecompany is engaged in real estate development.
- Alembic Pharmaceuticals Europe Ltd: This wholly-owned subsidiary of the company was established to expand its business in Europe.
- Alnova Pharmaceuticals SA: This is a wholly-owned subsidiary of the company that was established to expand its business in Switzerland.
Key Personalities of Alembic Pharmaceuticals Limited
Pranav Amin, Managing Director
Pranav Amin has been the Managing Director of Alembic Pharmaceuticals Limited since 2016. He also heads the company’s international business unit. He drives the company through empowerment, involvement and autonomy.
Peer Comparison
Stocks | Market Cap (cr) | Market Price (₹) | 52 Week Low-High (₹) |
---|---|---|---|
Supriya Lifescience Ltd | ₹3,326.35 |
413.8 11.50 (2.86%) |
397.5 - 424 |
Celestial Biolabs Ltd | ₹4.56 |
1.75 0.00 (0.00) |
1.75 - 1.8 |
JFL Life Sciences Ltd | ₹47.29 |
43 2.10 (5.13%) |
43 - 43 |
Procter & Gamble Health Ltd | ₹7,836.36 |
4720.85 8.35 (-0.18%) |
4636.55 - 4769.95 |
Veerhealth Care Ltd | ₹41.98 |
26 0.00 (0.00) |
26 - 26 |
Popular Stocks
What's Trending
Alembic Pharmaceuticals FAQs
What is the Share price of Alembic Pharmaceuticals (APLLTD)?
Can I buy Alembic Pharmaceuticals (APLLTD) shares?
How do I buy Alembic Pharmaceuticals (APLLTD) from Angel One?
- Direct investment: You can buy Alembic Pharmaceuticals (APLLTD) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Alembic Pharmaceuticals (APLLTD) shares.
Is Alembic Pharmaceuticals a Debt free Company?
No, Alembic Pharmaceuticals is not a debt free company.
What is the main business of Alembic Pharmaceuticals?
The main business of Alembic Pharmaceuticals is to develop and manufacture generic pharmaceutical substances, intermediates, and pharmaceutical products.
Who are the promoters of Alembic Pharmaceuticals?
The main promoters of Alembic Pharmaceuticals include Nirayu Limited, Alembic Limited, Chirayu Ramanbhai Amin, Malika Chirayu Amin, Pranav Chirayu Amin, Shaunak Chirayu Amin, Udit Chirayu Amin, Inaaya Shaunak Amin, Naintara Shaunak Amin, Ranvir Pranav Amin, and Samira Pranav Amin.
What are the Subsidiaries that comes under Alembic Pharmaceuticals?
The main subsidiaries that come under Alembic Pharmaceuticals are Alembic Pharmaceuticals Inc., Alembic Global Holding SA, Alembic Pharmaceuticals Australia Pty Ltd, Alembic Pharmaceuticals Europe Ltd., Alnova Pharmaceuticals SA, Alembic Labs LLC, Alembic Pharmaceuticals Canada Ltd., and Genius LLC.